Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Status:
Recruiting
Trial end date:
2024-10-13
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label and pragmatic clinical trial to evaluate the primary
efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19)
with concurrent BTK inhibitor in patients with relapsed or refractory B cell lymphoma